Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by jayjay2020on Apr 05, 2019 4:10pm
105 Views
Post# 29589840

RE:RE:RE:RE:Cool...we get to sell a whooping 1000kgs

RE:RE:RE:RE:Cool...we get to sell a whooping 1000kgs
SandstoneMiner wrote: Dont forget Netherlands, one of those articles mentioned over half of german pharmaceutical sales came from Netherlands and the rest from Canada. Not APHA though as apparently they are not EU certified yet.
Medicalweedz wrote: That's German grow. What that doesn't cover the rest will be exported from Canada


Yukon you fail to see the business model.  Every country will stop importing MJ if they can and have it home grow.  The individual countries will have better control of the quality, pricing, more so they generate tax dollars for themselves.  Not to mention MJ creates many jobs for the local economy.  Importing will be a for the most part non existent.   Germany will one day stop importing .  They have no reason to continue once the cultivation licences are in place and they can gro enough to meet their demand.  APHA, ACB and WAYL have the first mover advantage. APHA is far ahaed because they have CC pharma to package and distribute the product and they will have a few pain centres set up through Schoneberg hospital.  Do you get the model now?  APHA grows the product .  CC pharma packages/ lables the product .  The doctors at Schoneberg and other pain centers which they will set up prescribe the product. CC Pharma ships it out product to the pharmacies.  The prescriptions are then filled.   I see it as pure top to bottom channel.  It does not get better. 
Bullboard Posts